Tharimmune, Inc. announced on April 30, 2025, the appointment of Clay Kahler and Gary Stetz to its Board of Directors. These appointments increase the Tharimmune Board to nine Directors.
The company also reported in a Form 8-K filed on April 25, 2025, that Directors Leonard Mazur and Lynne Bui, M.D., departed from the Board. These changes reflect an evolution in the company's governance structure.
The addition of Mr. Kahler and Mr. Stetz aims to bring new expertise and perspectives to the board. This move is part of Tharimmune's ongoing efforts to strengthen its strategic leadership as it advances its pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.